Lilly To Pay Utah $24M Over Zyprexa Marketing

Law360, New York (November 11, 2009, 1:19 PM EST) -- Eli Lilly & Co. will pay Utah $24 million in the latest state settlement over the pharmaceutical giant's alleged off-label marketing of the antipsychotic Zyprexa, state officials said Wednesday.

Utah Attorney General Mark Shurtleff announced that the state reached the settlement after a four-year investigation that found Lilly's sales force illegally promoted the drug for uses not approved by the U.S. Food and Drug Administration and concealed side effects of significant weight gain and obesity.

It is Utah's largest settlement with a pharmaceutical company for unlawful...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.